KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.

Ruth E Langley, Duncan C Gilbert, Stephen Mangar, Stuart Rosen, Ellie Bourmaki, Hannah L Rush, Subramaniam Kananga Sundaram, Abdulla Alhasso, Roger Kockelbergh, Hoda Abdel-Aty, Claire L Amos, Louise Brown, Simon Brown, Charlene Carvalho, Kitty Chan, Gerald Collins, William Cross, John Deighan, Sanjay Dixit, Trinh Duong, James Dyer, Joanna Gale, Silke Gillessen, Anna Griffiths, Marc Laniado, Anna Lydon, Neil McPhail, Archie MacNair, Sanjeev Madaan, John Marshall, David Matheson, Robin Millman, Wael Mohamed, Laura Murphy, Krishna Narahari, Christopher Parker, Miguel Panades, Alvan Pope, Arpita Raval, Angus Robinson, Martin Russell, Christopher Scrase, Matthew Sydes, Rafal Turo, Ram Venkitaraman, Simona Wade, Howard Kynaston, Gerhardt Attard, Nicholas D James, Noel Clarke, Mahesh K Parmar, Matthew Nankivell, STAMPEDE-1 and PATCH Investigators

N Engl J Med 394(16) 1595-1607

PMID41880608
PMCID-
DOI10.1056/NEJMoa2511781
发表日期2026-03-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Transdermal estradiol (tE2) is an alternative to luteinizing hormone-releasing hormone (LHRH) agonists as androgen-deprivation therapy in patients with prostate cancer. With tE2, testosterone is suppressed, and the side effects of estrogen depletion due to LHRH agonists and the thromboembolic side effects of oral estrogen are mitigated. METHODS: In this phase 3, noninferiority, randomized trial, we assigned men with locally advanced (M0 and N0 or N+) prostate cancer to receive tE2 patches (100 μg of estradiol every 24 hours) or LHRH agonists. The primary outcome was 3-year metastasis-free survival. The noninferiority margin was 4 percentage points; this corresponded to a target hazard ratio of 1.31, as derived from the observed 3-year metastasis-free survival in the LHRH agonist group. Secondary outcomes included castrate levels of testosterone (<1.7 nmol per liter), overall survival, and safety. RESULTS: Between 2007 and 2022, we recruited 1360 patients at 75 U.K. centers. The median age of the patients was 72 years (interquartile range, 68 to 77); 85% had a T3 tumor stage and 65% an N0 nodal stage. Observed 3-year metastasis-free survival was 87.1% with tE2 and 85.9% with LHRH agonists (hazard ratio for confirmed metastasis or death, 0.96; upper limit of the one-sided 95% confidence interval [CI], 1.11, which met the criterion for noninferiority). Among patients continuing the assigned treatment, castrate levels of testosterone were sustained during the first year after randomization in 85% in each group. Observed 5-year overall survival was 81.1% with tE2 and 79.2% with LHRH agonists (hazard ratio for death, 0.90; 95% CI, 0.75 to 1.07). During treatment, hot flashes occurred in 44% of the patients who received tE2 and 89% of those who received LHRH agonists (grade ≥2 events, 8% and 37%, respectively) and gynecomastia in 85% and 42% (grade ≥2 events, 37% and 9%). CONCLUSIONS: In patients with locally advanced prostate cancer, tE2 was noninferior to LHRH agonists for 3-year metastasis-free survival, with a lower incidence of hot flashes but a higher incidence of gynecomastia. (Funded by Cancer Research U.K. and the U.K. Research Institute Medical Research Council; PATCH ClinicalTrials.gov number, NCT00303784; STAMPEDE-1 ClinicalTrials.gov number, NCT00268476.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。